Perspectives in the prevention of uterine cervix carcinoma

Česká verzia

Authors: doc. MUDr. Ph.D. Martin Redecha ¹; MUDr. Mikuláš Redecha ²; doc. MUDr. Miroslav Korbeľ; CSc. ¹; MUDr. Zuzana Nižňanská, Ph.D. ¹
Authors place of work: I. gynekologicko-pôrodnícka klinika LFUK, Bratislava ¹; II. gynekologicko-pôrodnícka klinika LFUK, Bratislava ²
Published in the journal: Prakt Gyn 2008; 12(1): 42-46

Práce je převzata z časopisu Praktická gynekológia 2007; 14(4): 148-153 na základě spolupráce redakcí našich časopisů a dohody o výměně odborných prací.

Summary

Sexually transmitted HPV infection is the basic etiological factor of uterine cervix carcinoma. Despite the existence of effective screening methods in the secondary prevention, the incidence of cervical carcinoma is still too high. Today, vaccination against HPV is a powerful tool in the primary prevention of this disease. In the close future, we will be able to significantly lower the occurrence of this type of cancer. However, classical prebioptic diagnostic methods will still play an important role in the prevention (Fig. 3, Tab. 1 [25]).

Key words:
uterine cervix carcinoma, HPV, vaccination, screening

Zdroje

1. Arbyn M, Paraskevaidis E, Martin-Hirsch P. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005; 99(Suppl 1): 7-11.

2. Asif M, Siddiqui A, Perry M. Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs 2006; 66: 1263-1271.

3. Baseman JG, Koutsky JA. The eoidemiology of human papillomavirus infections. J Clin Virol 2005; 32: 16-24.

4. Castellsagu´e X, Diaz M, de Sanjose S. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 303–315.

5. Clifford GM, Smith JS, Plummer M. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003; 88: 63-73.

6. Fife KH, Wheeler CM, Koutsky LA. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 2004; 22: 2943-2952.

7. Franceschi S. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res 2005; 166: 277-297.

8. Goldie SJ, Kohli M, Grima D et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-615.

9. Harper DM, Franco EL, Wheeler C. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with humanpapillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.

10. Harper DM, Franco EL, Wheller CM. Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.

11. Liu DW, Chang JL, Tsao YP et al. Covaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM–CSF can elicit strong and prolonged neutralizing antibody. Int J Cancer 2005; 113: 93-100.

12. Mandic A, Vujkov T. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol 2004; 15: 197-200.

13. Mao C, Koutsky LA, Ault KA. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107: 18-27.

14. Mayrand MH, Duarte-Franco E, Coutlee F. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006; 119: 615-623.

15. Munoz N, Bosch FX, Castellsague X. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.

16. Nardelli-Haefliger D, Lurati F, Wirthner D. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005; 23: 3634-3641.

17. Olsson SE. For the Future II Study Group. Post-infection prophylaxis of a quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine: a combined analysis. The 6th International Multidisciplinary Congress of the European Research Organization on Genital Infection and Neoplasia. Abstract. Paris 2006: 23-26.

18. Parkin DM, Bray F, Ferlay J. Global cancer statistics 2002. Cancer J Clin 2005; 55: 74-108.

19. Redecha M, Korbeľ M, Nižňanská Z. Výskyt karcinómu maternicového krčka na Slovensku v rokoch 1990-2000. Gynekol Prax 2004; 2: 118-124.

20. Riedesel JM, Rosenthal SL, Zimet GD. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol 2005; 18: 391-398.

21. Sasagawa T, Tani M, Basha W. A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res 2005; 110: 81-90.

22. Schiller J, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2: 343-347.

23. Schreckenberger C, Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004; 16: 485-491.

24. Villa LL, Costa RL, Petta CA. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.

25. Yang BH, Bray FI, Parkin DM. Cervical cancer as a priority for prevention in different world regions: An evaluation using years of life lost. Int J Cancer 2004; 109: 418-424.